Kenvue (NYSE:KVUE) Stock Sold Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on September 04th, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on July 17th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

Kenvue Stock Performance

NYSE:KVUE opened at $18.70 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The firm has a market cap of $35.92 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 1.67 and a beta of 0.46. The firm’s fifty day moving average price is $19.18 and its 200 day moving average price is $18.26. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $20.69.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same quarter last year, the business posted $0.29 EPS. The firm’s revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a dividend of $0.21 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, August 12th. Kenvue’s dividend payout ratio is 96.55%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. UBS Group cut their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Barclays upped their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $19.27.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently added to or reduced their stakes in KVUE. BlackRock Inc. acquired a new stake in shares of Kenvue in the second quarter valued at approximately $2,882,279,000. California State Teachers Retirement System boosted its position in shares of Kenvue by 1,695.1% during the second quarter. California State Teachers Retirement System now owns 56,438,843 shares of the company’s stock worth $1,078,546,000 after buying an additional 53,294,807 shares during the period. Pentwater Capital Management LP bought a new position in Kenvue in the 2nd quarter worth approximately $977,094,000. Norges Bank acquired a new stake in Kenvue in the 4th quarter valued at approximately $756,862,000. Finally, Independent Franchise Partners LLP grew its stake in shares of Kenvue by 56.3% in the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after purchasing an additional 17,343,785 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.